Scarica l'app Stockscreener
0.3434
4.35%
-0.0156
Dopo l'orario di chiusura:
.36
0.0166
+4.83%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ITRM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.359
Aprire:
$0.3606
Volume 24 ore:
411.48K
Relative Volume:
0.41
Capitalizzazione di mercato:
$18.30M
Reddito:
-
Utile/perdita netta:
$-24.08M
Rapporto P/E:
-0.4006
EPS:
-0.8572
Flusso di cassa netto:
$-14.75M
1 W Prestazione:
+2.51%
1M Prestazione:
-23.38%
6M Prestazione:
-63.19%
1 anno Prestazione:
-80.92%
Intervallo 1D:
$0.342
$0.3757
Intervallo di 1 settimana:
$0.305
$0.38
Portata 52W:
$0.26
$1.85
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Nome
Iterum Therapeutics Plc
Settore
Industria
Telefono
(872) 225-6077
Indirizzo
3 DUBLIN LANDINGS, DUBLIN 1
Confronta ITRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.3434 | 19.13M | 0 | -24.08M | -14.75M | -0.8572 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Downgrade | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie
Will Iterum Therapeutics plc stock benefit from sector rotationInflation Watch & Safe Capital Growth Stock Tips - ulpravda.ru
Can Iterum Therapeutics plc stock deliver surprise earnings beatWeekly Trade Report & Expert Curated Trade Setup Alerts - ulpravda.ru
Is Iterum Therapeutics plc stock overvalued by current metrics2025 AllTime Highs & Weekly High Return Stock Opportunities - ulpravda.ru
Why Iterum Therapeutics plc stock remains a top recommendationStock Buyback Updates & Market Monitoring and Alerts - ulpravda.ru
Will Iterum Therapeutics plc stock benefit from green energy trends2026 world cup usa national team qualification star players possession football odds analysis analysis - ulpravda.ru
Iterum Therapeutics expands market access for ORLYNVAH antibiotic - Investing.com
Iterum Therapeutics provides business update - marketscreener.com
Iterum Therapeutics Provides Business Update - The Manila Times
New antibiotic ORLYNVAH could reach 34M+ people pending FDA feedback - Stock Titan
Analyzing Iterum Therapeutics (NASDAQ:ITRM) & Savara (NASDAQ:SVRA) - Defense World
Why hedge funds are buying Iterum Therapeutics plc stockWeekly Trade Analysis & Capital Efficient Trade Techniques - Улправда
Iterum Therapeutics secures major PBM agreement for antibiotic By Investing.com - Investing.com Nigeria
Iterum Therapeutics (ITRM) Secures Key PBM Agreement and Expands Patent Portfolio - GuruFocus
Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com
New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan
Iterum Therapeutics faces Nasdaq listing compliance challenge - MSN
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge - The Globe and Mail
Iterum Therapeutics receives Nasdaq notice on listing compliance By Investing.com - Investing.com Australia
Iterum Therapeutics plc Stock Analysis and ForecastEarnings Forecast Updates & Fast Profit Stock Ideas - earlytimes.in
Iterum Therapeutics receives Nasdaq notice on listing compliance - Investing.com
Iterum Therapeutics (NASDAQ: ITRM) discloses Nasdaq delisting risk on value, price - Stock Titan
Iterum Therapeutics Plc (ITRM) can make a big difference with a little luck - setenews.com
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH By Investing.com - Investing.com Nigeria
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH - Investing.com
ITRM Expands ORLYNVAH Access and Secures Key Medicare Part D Agr - GuruFocus
Iterum Therapeutics (Nasdaq: ITRM) inks Medicare Part D deal, EU patent to 2039 - Stock Titan
Iterum Therapeutics (ITRM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Taking on analysts’ expectations and winning: Iterum Therapeutics Plc (ITRM) - setenews.com
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Iterum’s antibiotic ORLYNVAH now available through McKesson By Investing.com - Investing.com Nigeria
Iterum’s antibiotic ORLYNVAH now available through McKesson - Investing.com
Iterum Therapeutics (ITRM) Expands Product Availability and FDA Clearance - GuruFocus
Iterum (NASDAQ: ITRM) Adds McKesson for ORLYNVAH as Sulopenem Disc Gains FDA 510(k) - Stock Titan
Q3 2025 Iterum Therapeutics PLC Earnings Call Transcript - GuruFocus
Is Iterum Therapeutics plc stock attractive after correctionPortfolio Update Report & Growth Oriented Trading Recommendations - newser.com
Why retail investors favor Iterum Therapeutics plc stockJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Can Iterum Therapeutics plc stock maintain operating marginsJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Iterum Therapeutics director Dunne buys $2,191 in shares By Investing.com - Investing.com Nigeria
Dir Dunne Buys 6,000 ($2.2K) Of Iterum Therapeutics PLC [ITRM] - TradingView
[Form 4] Iterum Therapeutics plc Insider Trading Activity - Stock Titan
Can Iterum Therapeutics plc stock resist market sell offs2025 Big Picture & Fast Gain Swing Alerts - newser.com
Iterum Therapeutics Plc Azioni (ITRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):